INTRODUCTION
Osteoclast-mediated bone resorption is known to be a critical process in the development and physiology of the skeleton (1) . Multinucleated mature osteoclasts repeatedly resorb old bone matrix and migrate to future bone resorption sites in a process referred to as the resorption cycle (2, 3) . The resorption cycle of osteoclasts plays an important role in bone remodeling (4) . In the initial stage of bone resorption, osteoclasts adhere to the bone surface via interactions with integrin, a large family of cell adhesion receptors. Integrin consists of  and  subunits and transmits cell-cell and cell-extracellular matrix (ECM) interactions (5) . Binding of integrin to its ligand activates signal transduction pathways, which lead to cell adhesion, spreading, and cytoskeletal reorganization. Among integrin isoforms, integrin v3 is predominantly expressed on the cytoplasmic surface of osteoclasts and interacts with bone matrix proteins such as osteopontin (OPN) and bone sialoprotein II (6) as well as participates in adhesion to bone, cytoskeletal reorganization, and bone resorption. It is also known that macrophage colony-stimulating factor (M-CSF) and hepatocyte growth factor (HGF) mediate osteoclast adhesion and spreading via integrin v3-dependent mode (5) . Coupling between v3 and its binding partner triggers multiple signaling factors, such as phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), phospholipase C (PLC), proline-rich tyrosine kinase (PYK2), c-Src, and small GTPases (7) (8) (9) (10) (11) (12) . Specifically, binding of M-CSF to its receptor, c-Fms, activates v3 and subsequent downstream signaling molecules, including PLC, PI3K, and small GTPases, via "inside-out" signaling (5, 7, 10) . Further, direct interaction of OPN with v3 was found to activate PYK2, c-Src, PI3K, and PLC via "outside in" signaling (10, 13) as well as enhance osteoclast survival and function by facilitating the Ca 2＋ -dependent transcription factor NFATc1 pathway (14) , which is essential for osteoclast differentiation.
PLC is a common downstream effector for integrin v3-and M-CSF-mediated signaling in pre-fusion osteoclasts (10) . Suppression of PLC2 has been shown to reduce cell adhesion, migration, and bone resorption in osteoclasts (15) . PLC generates diacylglycerol and inositol-triphosphate, leading to PKC activation and calcium release from the endoplasmic reticulum (16) . PKC is thought to play a key role in integrin v3-mediated signal transduction, osteoclast migration, and bone resorption (12) . On the contrary, the functional roles of other PKC isoforms in osteoclast adhesion and spreading have not been fully understood. PKC is known to activate downstream small GTPase cascades involved in the modulation of integrin-mediated cytoskeletal organization (17, 18) . For example, small GTPases (Rho and Rac) have been reported to organize and maintain cellular cytoskeletal http://bmbreports.org BMB Reports structures in osteoclasts (19) . Despite osteoclast adhesion and spreading being associated with various signal molecules, sequential coordination between signal modulators in osteoclast adhesion and spreading induced by M-CSF and OPN is not well understood. Here, we observed that consecutive activation of the PLC/PKC/Rac1 signal axis governs osteoclast adhesion and spreading induced by M-CSF and OPN. Further, the results show that signal activation via PLC/PKC/RhoA plays a negative role in osteoclast spreading but not osteoclast adhesion.
RESULTS AND DISCUSSION
Osteoclast adhesion and spreading mediated by M-CSF and OPN share integrin v3/PLC signaling Growth factors and extracellular matrix proteins have been identified as activators for inducing cell adhesion and spreading in an integrin-dependent manner (5, 6, 10, 20) . We first examined the effects of M-CSF and OPN on osteoclast adhesion and spreading. M-CSF and OPN promoted adhesion and spreading of mature osteoclasts ( Fig. 1 ). M-CSF and OPN in osteoclasts are known to converge at integrin v3 activation via "inside-out" signaling and "outside-in" signaling, respectively (5, 6). Thus, we investigated whether or not enhanced adhesion and spreading induced by M-CSF or OPN in mature osteoclasts are dependent upon integrin v3. Treatment with functional blocking antibodies against integrins v and 3 suppressed osteoclast adhesion and spreading in response to M-CSF and OPN ( Fig. 2A and B) . These results indicate that M-CSF and OPN facilitate osteoclast adhesion and spreading via an integrin v3-dependent pathway. Since integrin v3 was reported to activate PLC1 and PLC2 as well as foster their recruitment to v3 in pre-fusion osteoclasts (10), we also examined whether or not PLC activation is required for M-CSF-and OPN-induced adhesion and spreading in osteoclasts. Treatment with PLC inhibitor (U73122) blocked M-CSF-and OPN-induced osteoclast adhesion and spreading in a dose-dependent manner ( Fig. 2C  and D) . These results indicate that M-CSF-and OPN-induced osteoclast adhesion and spreading progress via "inside-out" signaling and "outside-in" signaling depending on integrin v3, respectively, and share v3 and PLC signaling.
PLC activates PKC and PKC during osteoclast adhesion and spreading
PKCs are known to be downstream effectors of integrin-http://bmbreports.org mediated PLC signaling (21) and M-CSF has been reported to specifically stimulate PKC and PKC among PKC isoforms in osteoclast precursors (22) . Here, we investigated the relationship between PLC and PKC upon treatment with M-CSF or OPN in mature osteoclasts. PKC and PKC were efficiently translocated into the osteoclastic cytoplasmic membrane in response to M-CSF or OPN (Fig. 3A and B) . Moreover, phosphorylation levels of PKC and PKC in membrane fractions were elevated after treatment with M-CSF or OPN. However, active forms of PKC and PKC induced by M-CSF or OPN disappeared after treatment with PLC inhibitor (U73122). These findings indicate that M-CSF or OPN induces serial activation of PLC and PKC/PKC signal during osteoclast adhesion and spreading. Further, we observed that osteoclast adhesion and spreading induced by M-CSF or OPN were suppressed by treatment with PKC inhibitor (rottlerin) but not PKC inhibitor (Gö6976) (Fig. 3C and D) . Interestingly, PKC inactivation led to an approximately 1.5-fold increase in M-CSF-and OPN-induced osteoclast spreading compared to the control, indicating that PKC negatively regulates osteoclast spreading. These results indicate that PKC is necessary for both osteoclast adhesion and spreading, whereas PKC plays a negative role in osteoclast spreading.
PKC and PKC selectively regulate activities of RhoA and Rac1 during osteoclast adhesion and spreading
Small GTPases have been reported to regulate integrindependent cell morphological changes, including formation of stress fibers, lamellipodia, and filopodia (5, 23, 24) . It is also known that small GTPases (Rho and Rac) regulate cell spreading and cytoskeleton organization (2, 19) . Since small GTPases are reported to be downstream effectors of the PKC signaling pathway (22, 25), we investigated whether or not M-CSF or OPN is involved in regulating the activities of small GTPases (RhoA and Rac1) in osteoclasts. As shown in Fig. 4A and B, elevation of RhoA activity by M-CSF or OPN was reduced by treatment with either PKC inhibitor (Gö6976) or http://bmbreports.org BMB Reports PKC inhibitor (rottlerin). Specifically, the stimulatory effect of M-CSF and OPN on Rac1 activity was suppressed by treatment with PKC inhibitor but not PKC inhibitor. These results indicate that PKC controls both RhoA and Rac1 activities, and PKC regulates only RhoA activity during M-CSF-and OPN-induced osteoclast stimulation. Further, we observed that osteoclast adhesion and spreading induced by M-CSF or OPN were suppressed by treatment with Rac1 inhibitor (NSC23766) but not RhoA inhibitor (Y27632) (Fig. 4C and D) . Particularly, RhoA inactivation led to an approximately 1.5-fold increase in M-CSF-and OPN-induced osteoclast spreading compared to the control, indicating that RhoA signaling is involved in inhibition of osteoclast spreading. The combined results indicate that PKC-mediated Rac1 activation is involved in both osteoclast adhesion and spreading, whereas PKC-mediated RhoA activation negatively regulates osteoclast spreading but not osteoclast adhesion. Seesaw-like crosstalk between extracellular signal-regulated kinase (ERK) and p38 activation has been reported to occur during RANKL-induced osteoclastogenesis (26, 27) . Treatment with p38 inhibitors resulted in increased ERK activation, and ERK inhibitors caused an increase in p38 activation. Consistent with these results, it is also possible that the treatment of PKC or RhoA inhibitors may lead to the activation of PKC or Rac1. For bone resorption, multinucleated osteoclasts derived from hematopoietic stem cells adhere to the bone surface via integrin v3 present in the cytoplasmic membrane, resulting in the formation of a large and dense F-actin ring called the sealing zone and ruffled border (1, 2, 28) . Osteoclast adhesion and subsequent spreading are critical in the initial stage of bone resorption by osteoclasts. Afterward, osteoclasts can resorb old or damaged bone by sequential repeated processes, including cell contraction, cell spreading by disassembling the sealing zone, and cell migration.
Here, we analyzed the regulatory mechanisms underlying osteoclast adhesion and spreading induced by M-CSF or OPN. As summarized in Fig. 4E , integrin v3 in the surface of osteoclasts is activated by binding of M-CSF to c-Fms receptor in a process termed "inside-out" signaling. Further, OPN directly binds to and stimulates integrin v3 in a process termed "outside-in" signaling. Integrin v3 activated by M-CSF or OPN allows the initial adhesion of osteoclasts for bone resorption and subsequent spreading process via PLC/PKC/Rac1 signaling. Additionally, we observed that PLC/PKC/RhoA signaling stimulated by M-CSF or OPN plays a negative role in osteoclast spreading with no effect on osteoclast adhesion. Overall, our findings suggest that osteoclast adhesion and spreading are differentially regulated via PLC/PKC-PKC/RhoA-Rac1 signaling.
MATERIALS AND METHODS

Antibodies and inhibitors
Antibodies specific for phosphorylated-PKC and phosphorylated-PKC were from Cell Signaling (Beverly, MA, USA); antibodies for PKC, PKC, integrins v and 3, and actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). U73122 was obtained from Sigma-Aldrich (St. Louis, MO, USA). Gö6976, rottlerin, Y27632, and NSC23766 were from Calbiochem (San Diego, CA, USA).
Osteoclast differentiation
Bone marrow-derived monocytes were isolated from the long bones of 6-week-old C57BL/6 male mice by flushing the bone marrow cavity with minimum essential medium-alpha (-MEM; Hyclone, Logan, Utah, USA). Cells were centrifuged and the red blood cells were removed using red blood cell lysis buffer (Sigma-Aldrich). Next, cells were incubated with -MEM containing 10% fetal bovine serum (FBS; Hyclone) and M-CSF (5 ng/ml) for 12 h. The non-adherent cells were collected, plated on 100-mm culture dishes, and further cultured for 3 days with -MEM containing M-CSF (30 ng/ml) to generate bone marrow-derived osteoclast precursors. Osteoclast precursors were differentiated into osteoclasts in -MEM supplemented with M-CSF (30 ng/ml) and receptor activator of nuclear factor κB ligand (RANKL; 100 ng/ml) for 4 days with a change of medium on day 2.
Cell adhesion and spreading assays
Cell adhesion and spreading assays were performed as previously described (29) . 
Subcellular fractionation and immunoblot analysis
Subcellular fractionation of cytosolic and membrane proteins was carried out using a plasma membrane protein extraction kit (Biovision, Milpitas, CA, USA) according to the manufacturer's protocols as described previously (29) . After cells were lysed with homogenization buffer (Biovision) and centrifuged at 12,000 × g for 30 min, the supernatants were collected as the cytosolic fraction. The pellets were solubilized with RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, 1% SDS, 1 mM PMSF, 1 mM Na3VO4, 1 mM glycerol phosphate, and protease inhibitor cocktail) and sonicated for 30 s on ice. After centrifugation at 10,000 × g for 30 min, the supernatants were collected as the membrane fraction. The fractionated proteins were denatured using SDS sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.1% bromophenol blue, and 50 mM dithiothreitol) and subjected to 10% SDS-PAGE. The separated proteins were electrotransferred to nitrocellulose membranes and probed with primary antibodies and appropriate HRP-conjugated secondary antibodies. All blots were then developed with ECL reagent (Abfrontier, Seoul, Korea).
Small GTPases activation assays
Small GTPase activation assays were performed using a small GTPase G-LISA activation assay kit (Cytoskeleton Inc., Denver, CO, USA) according to the manufacturer's procedures. To assess relative activities of small GTPases (RhoA and Rac1), the resultant absorbance was read at 450 nm using an ELISA microplate reader model 680 (Bio-Rad, Hercules, CA, USA).
Statistical analysis
All values are presented as means ± S.D. (n = 3). The difference among multiple groups was analyzed using one-way ANOVA analysis with Tukey's test. P value of ＜ 0.05 was considered to be significant. These analyses were performed using the program GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA).
